Risk Factors for Positive Posttransplantation Measurable Residual Disease in Patients with Acute Lymphoblastic Leukemia

被引：0
|
作者：
Wang, Yuewen [1 ]
Fu, Guomei [1 ]
Xu, Lanping [1 ]
Wang, Yu [1 ]
Cheng, Yi-Fei [1 ]
Zhang, Yuanyuan [1 ]
Zhang, Xiaohui [1 ]
Liu, Yanrong [1 ]
Liu, Kaiyan [1 ]
Huang, Xiao-Jun [2 ,3 ,4 ]
Chang, Ying-Jun [1 ]
机构：
[1] Peking Univ Peoples Hosp, Beijing, Peoples R China
[2] Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China
[3] Peking Univ Peoples Hosp, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Peking Univ Inst Hematol, Natl Clin Res Ctr Hematol Dis, Beijing, Peoples R China
[4] Chinese Acad Med Sci, Res Unit Key Tech Diag & Treatments Hematol Malig, Beijing, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182572
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] PREDICTING MEASURABLE RESIDUAL DISEASE FOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS POSTTRANSPLANTATION
    Wang, Yue-Wen
    Fu, Guo-Mei
    Xu, Lan-Ping
    Wang, Yu
    Cheng, Yi-Fei
    Zhang, Yuan-Yuan
    Zhang, Xiao-Hui
    Liu, Yan-Rong
    Liu, Kai-Yan
    Huang, Xiao-Jun
    Chang, Ying-Jun
    BONE MARROW TRANSPLANTATION, 2024, 59 : 498 - 498
  • [2] Evaluation and management of measurable residual disease in acute lymphoblastic leukemia
    Abou Dalle, Iman
    Jabbour, Elias
    Short, Nicholas J.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [3] Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia
    Hein, Kyaw
    Short, Nicholas
    Jabbour, Elias
    Yilmaz, Musa
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2022, 12 : 7 - 16
  • [4] Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients
    Saygin, Caner
    Cannova, Joseph
    Stock, Wendy
    Muffly, Lori
    HAEMATOLOGICA, 2022, 107 (12) : 2783 - 2793
  • [5] Measurable Residual Disease in Acute Lymphoblastic Leukemia: Techniques and Therapeutic Utility
    Muffly, Lori
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (07) : 419 - 421
  • [6] Molecular and cellular markers for measurable residual disease in acute lymphoblastic leukemia
    Juarez-Avendano, Gerardo
    Mendez-Ramirez, Nereida
    Luna-Silva, Nuria C.
    Gomez-Almaguer, David
    Pelayo, Rosana
    Balandran, Juan C.
    BOLETIN MEDICO DEL HOSPITAL INFANTIL DE MEXICO, 2021, 78 (03): : 159 - 170
  • [7] Measurable residual disease in acute lymphoblastic leukemia: How low is low enough?
    Logan, Aaron C.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2022, 35 (04)
  • [8] Measurable Residual Disease in Acute Lymphoblastic Leukemia: Optimization and Innovation in 2021 and Beyond
    Muffly, Lori
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S85 - S87
  • [9] Measurable Residual Disease (MRD)-directed therapy for Acute Lymphoblastic Leukemia (ALL)
    Nagafuji, Koji
    CANCER SCIENCE, 2025, 116 : 1797 - 1797
  • [10] Measurable residual disease in childhood B-cell acute lymphoblastic leukemia
    Gale, Robert Peter
    BLOOD SCIENCE, 2022, 4 (04): : 209 - 210
12345